As you say tada, lots of wiggle room.  In addition to what you mentioned is the opportunity in complement diseases which David Kideckel said was what excited him about RVX more than anything else.

What I find most exciting about the company produced EV chart is that if BETOnMACE is successful and on schedule then the EV as per the chart should fall somewhere between $3.9B and $7.2B USD by late this year early next, now that US and EU approvals will be on a similar path.  I would imagine that market cap will start to approach EV if and when BETOnMACE reaches a successful conclusion.  JMO